DARWIN EU® Prevalence of rare blood cancers in Europe

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study

Non-interventional study

• Scope of the study:
  Disease epidemiology
• Data collection methods:
  Secondary data collection
• Non-interventional study design:
  Cohort

  Other
• Non-interventional study design, other:
  Population-based

Study drug and medical condition

• Medical condition to be studied:
  Follicular lymphoma

  Diffuse large B-cell lymphoma

  Plasma cell myeloma

  Chronic lymphocytic leukaemia

  Acute myeloid leukaemia

  Acute lymphocytic leukaemia

Population studied

• Short description of the study population:
  The study included all individuals reported in the five European databases, including IPCI, SIDIAP, CPRD, IQVIA LPD Belgium, and IQVIA DA Germany, to determine the prevalence of haematological cancers.
• Age groups:
  Preterm newborn infants (0 – 27 days)

  Term newborn infants (0 – 27 days)

  Infants and toddlers (28 days – 23 months)

  Children (2 to < 12 years)

  Adolescents (12 to < 18 years)

  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Special population of interest:
  Other
• Special population of interest, other:
  Patients with haematological cancers
• Estimated number of subjects:
  10000000

Study design details

• Main study objective:
  To estimate the prevalence of rare blood cancers (follicular lymphoma, diffuse Large B-Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Acute Lymphocytic Leukaemia)
• Outcomes:
  Follicular lymphoma, diffuse Large B-Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Acute Lymphocytic.
• Data analysis plan:
  5-year partial prevalence will be estimated for each outcome of interest.

Documents

Results tables

DARWIN_EU_Study_Report_C1-001_V3.2